Verzenio is indicated for the treatment of hormone receptor–positive (HR+), human epidermal growth factor receptor 2−negative (HER2–) advanced or metastatic breast cancer (MBC):
- In combination with fulvestrant for women with disease progression following endocrine therapy
- In combination with an aromatase inhibitor (AI) for postmenopausal women as initial endocrine-based therapy
- As a single agent for adult patients with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting
Verzenio Continuous Care
You and your patients can find information about the Verzenio Continuous Care™ Support Program at verzenio.com
Helpful information for preparing documentation for Verzenio use
Verzenio is available through contracted specialty pharmacies and authorized distributors. See a list of specialty pharmacies.